4.6 Review

Therapeutic Strategies for Targeting IL-1 in Cancer

期刊

CANCERS
卷 13, 期 3, 页码 -

出版社

MDPI
DOI: 10.3390/cancers13030477

关键词

IL-1-blockade; clinical trials; cancer; immunotherapy; adoptive T cell therapy; chimeric antigen receptor T cells; CAR

类别

资金

  1. Marie Sklodowska-Curie Program Training Network for the Immunotherapy of Cancer - H2020 Program of the European Union [641549]
  2. Marie Sklodowska-Curie Program Training Network for Optimizing Adoptive T Cell Therapy of Cancer - H2020 Program of the European Union [641549, 955575]
  3. Hector foundation
  4. International Doctoral Program i-Target: Immunotargeting of Cancer - Elite Network of Bavaria
  5. Melanoma Research Alliance [409510]
  6. Else Kroner-Fresenius-Stiftung
  7. German Cancer Aid
  8. Ernst Jung Stiftung
  9. LMU Munich's Institutional Strategy LMUexcellent within the framework of the German Excellence Initiative
  10. Bundesministerium fur Bildung und Forschung Project Oncoattract
  11. European Research Council [756017]
  12. German Research Foundation (DFG)
  13. Fritz-Bender Foundation
  14. Jose-Carreras Foundation

向作者/读者索取更多资源

Interleukin-1 cytokines play a crucial role in inflammation and have implications in cancer research. Clinical trials have shown the potential of IL-1 blockade in cancer treatment, but it may also lead to immune toxicities. Current research focuses on utilizing IL-1 blocking agents to enhance the efficacy and safety of adoptive T cell therapy.
Simple Summary Interleukin-1 cytokines are key proinflammatory cytokines which have been implicated with differing pro- and antitumorigenic properties. Recent years have brought exciting insights and developments in IL-1-targeted therapies. Here, we present an overview of past and present research focusing on the role of IL-1 in cancer, with a special focus on clinical research and on therapeutic implications. With this, we strive to assist scientists in their future research objectives and to highlight possible directions for IL-1-targeting therapies in the coming years. Since its discovery, interleukin-1 has been extensively studied in a wide range of medical fields. Besides carrying out vital physiological functions, it has been implicated with a pivotal role in the progression and spreading of different cancer entities. During the last years, several clinical trials have been conducted, shedding light on the role of IL-1 blocking agents for the treatment of cancer. Additionally, recent developments in the field of immuno-oncology have implicated IL-1-induced signaling cascades as a major driver of severe chimeric antigen receptor T cell-associated toxicities such as cytokine release syndrome and immune effector cell-associated neurotoxicity. In this review, we summarize current clinical trials investigating the role of IL-1 blockade in cancer treatment and elaborate the proposed mechanism of these innovative treatment approaches. Additionally, we highlight cutting-edge developments utilizing IL-1 blocking agents to enhance the safety and efficacy of adoptive T cell therapy.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据